Vagus nerve stimulation in the treatment of epilepsy

Despite the fact that 15 different antiepileptic drugs are now available for use in Canada, about one-third of patients with epilepsy continue to have inadequate seizure control. Patients with pharmacoresistant epilepsy often experience various side effects of drug therapy, and the failure to control seizures can have devastating psychosocial, economic and health consequences, including serious accidents and cognitive or behavioural deterioration. In a small proportion of patients the effects of the epilepsy are so severe as to warrant brain surgery (usually of the temporal lobe). Innovative approaches have therefore been sought, including the ketogenic diet for children, implanted deep-brain stimulators (under study) and vagus nerve stimulation (VNS), which was approved in the US and Canada in 1997.

Why vagus nerve stimulation?

In 1985 Zabara proposed that VNS might disrupt the hypersynchronous brain electrical activity that underlies epileptic seizures, and subsequent studies in animal models of epilepsy suggested that this was the case. Although the mechanism of action of VNS is still not fully understood, it was felt that continual stimulation of the vagus nerve by an implantable electrical device might result in widespread bilateral activation or deactivation of the brain circuits thought to be involved with epileptic seizures. The reason for this lies in the neuroanatomical connections: afferent fibres from the vagus nerve comprise about 80% of the axons in the cervical vagus nerve, terminating on nuclei in the ipsilateral medulla and in the contralateral nucleus of the tractus solitarius (also in the brain stem). Inputs to these nuclei are then conveyed to widespread bilateral areas of the cerebral cortex, diencephalon and limbic system. The effects of VNS on these brain areas has been confirmed by positron emission tomography and functional MRI studies. Vagus nerve stimulators are not on-demand devices like cardiac pacemakers, which are designed to abort an event. Rather, they mostly function interictally — that is, between seizures, producing long-term alterations in the brain and thus decreasing seizure frequency. These long-term changes are not fully understood, as the characteristic interictal spike frequently seen on the electroencephalogram is largely unchanged.

Technique

The VNS is a battery-powered device very similar to a cardiac pacemaker. The latest model weighs 25 g and measures 7 mm in depth and 52 mm in diameter. The body of the device is implanted in the upper chest; 2 connecting wires with electrodes are placed subcutaneously and attached to the left vagus nerve in the carotid sheath. The surgery takes about 1 hour under general anesthesia, and the patient is usually discharged within a day. The generator is programmed by a wand attached to a laptop computer and placed over the generator. The customary cycle is a 30-second stimulation at 5-minute intervals. The stimulation intensity is gradually increased over weeks so the patient can accommodate to the mild discomfort (there is usually a mild tingling sensation and at times mild shock-like pain) and voice changes (resulting from recurrent laryngeal nerve stimulation).

The battery life is now up to 11 years, at which point the de-

| Table 1: Major clinical trials of vagus nerve stimulation for epilepsy |
|---------------------------------------------------------------|
| Study | No. of patients | Type of trial | Outcome measures | Results | p value | Comments |
|-------|-----------------|---------------|------------------|---------|---------|----------|
| The Vagus Nerve Stimulation Group | 114 | Randomized, parallel, double blind High v. low† stimulation | % change in seizure frequency compared with baseline | ~24.5% in high v. | < 0.01 | Short-term study (14-wk treatment phase) |
| Handforth et al | 199 | Randomized, parallel, double blind High v. low† stimulation | % change in seizure frequency compared with baseline | ~28% in high v. | 0.04 | Short-term study (3-mo treatment phase) |
| DeGiorgio et al | 195 | Longitudinal follow-up of patients from Handforth study High stimulation† | % change in seizure frequency at 3 and 12 mo compared with pre-implant baseline | ~34% at 3 mo and | < 0.0001 at both stages compared with pre-treatment baseline |

*All 3 studies involved adults with partial seizures with or without secondary generalization.
†High stimulation: current 0.25–3.0 mA, frequency 20–50 Hz, pulse width 500 microseconds, on time 30–90 seconds, off time 5–10 minutes.
‡Low stimulation: current 0.25–2.75 mA, frequency 1–2 Hz, pulse width 130 microseconds, on time 30 seconds, off time 60–180 minutes.
VNS has the distinct advantage of not depending on patient compliance: it functions automatically around the clock. However, it should be noted that patients rarely become seizure-free or able to eliminate their antiepileptic drugs entirely. VNS is therefore an adjuvant or palliative measure for patients in whom pharmacotherapy has proved inadequate, for whom traditional epilepsy surgery has failed or who are not candidates for traditional surgery.

Another advantage exists for patients who have auras as part of their seizures. Such patients can pass a magnet over the device during an aura to deliver an extra stimulation that may abort a full seizure (the magnet can also be taped over the device to turn it off if necessary). Other reported benefits include improvement in depression (a common problem in patients with epilepsy) and anecdotal claims for improved memory. Significant improvements in quality of life have been demonstrated with VNS.

The incidence of serious adverse events with VNS is low.6 Complications of the surgery such as wound infection and transient vocal cord paralysis occur in about 0.1% of cases. Although the left vagus nerve is used (because it has fewer parasympathetic fibres to the atria of the heart), transient sinus arrest may occur during testing of the device in the operating room. During the stimulation, patients often experience changes in voice quality or volume, and some experience neck, throat or ear pain, which may abate with a reduction in stimulation intensity or pulse width. The leads in the neck can occasionally break. A few patients complain of sleep disruption. There are reports of worsening of sleep apnea, and therefore the device is relatively contraindicated in patients known to have this problem. In severely mentally retarded children who need assistance for feeding, there is some evidence that the risk of aspiration may be increased during stimulation. MRI with a head coil is felt to be safe but diathermy is contraindicated.

The place of VNS in epilepsy therapy
As an adjuvant therapy VNS has comparable efficacy to most of the newer generation antiepileptic drugs, with a better side-effect profile. The devices are expensive, limiting more widespread use. Although VNS does not replace pharmacotherapy or traditional epilepsy surgery, some patients have been able to reduce the number of drugs they need to take and their dosage. The cost-effectiveness of VNS remains to be determined; additional clinical trials are necessary to answer questions around patient selection and the types of seizures VNS is most effective in preventing.

Alan Guberman
Division of Neurology
The Ottawa Hospital
Ottawa, Ont.

Competing interests: None declared.

References
1. Henry TR. Therapeutic mechanisms of vagus nerve stimulation. Neurology 2002;59(Suppl 4):S1-S14.
2. A randomized controlled trial of chronic vagus nerve stimulation for treatment of medically intractable seizures. The Vagus Nerve Stimulation Study Group. Neurology 1995;45:224-30.
3. Handforth A, DeGiorgio CM, Schachter SC, Uthman BM, Naritoku DK, Tecoma ES, et al. Vagus nerve stimulation therapy for partial-onset seizures: a randomized active-control trial. Neurology1998;51(1):48-55.
4. DeGiorgio CM, Schachter SC, Handforth A, Salinsky M, Thompson J, Uthman B, et al. Prospective long-term study of vagus nerve stimulation for the treatment of refractory seizures. Epilepsia 2000;41(9):1195-200.
5. Wheless JW, Maggio V. Vagus nerve stimulation therapy in patients younger than 18 years. Neurology 2002;59(6 Suppl 4):S21-S25.
6. Schachter SC. Vagus nerve stimulation therapy summary: five years after FDA approval. Neurology 2002;59(6 Suppl 4):S15-S20.